The prognostic value of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in low-risk and early-stage extranodal natural killer/T cell lymphoma
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06272-7 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Na Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell, Hemoglobins, Serum Albumin, Human, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive disease with grim prognosis. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been identified as a predictive marker for prognosis in various malignancies. However, the prognostic significance of the HALP score in the context of ENKTL has yet to be established. AIMS: Our objective was to assess the predictive power of the initial HALP score for ENKTL patients regarding their prognosis. METHODS: We conducted a retrospective analysis of 296 early-stage, low-risk ENKTL patients who were newly diagnosed and treated with asparaginase-based therapies. We evaluated the significance of HALP score as a predictor of response to treatment, overall survival (OS), and progression-free survival (PFS). RESULTS: The median follow‑up for all patients was 72 months. We identified that a low HALP score was associated with a poorer Eastern Cooperative Oncology Group (ECOG) performance status (PS), the presence of B symptoms, male gender, and increased lactate dehydrogenase (LDH) levels (all p < 0.05), as well as a suboptimal response to therapy (p = 0.006). In the prognostic index of natural killer cell lymphoma (PINK) model, low-risk ENKTL patients with a HALP score below 32.6 exhibited significantly worse 5-year OS at 51.8% compared to 75.5% for those with a HALP score of 32.6 or above (p < 0.001), and 5-year PFS at 47.1% compared to 69.9% (p < 0.001). Integrating Epstein-Barr virus (EBV)-DNA titer into the PINK model led to the development of an additional prognostic index, the PINK-E model. According to this model, low-risk ENKTL patients with a HALP score below 32.6 had significantly poorer 5-year OS at 46.0% compared to 73.1% for those with a HALP score of 32.6 or above (p < 0.001), and 5-year PFS at 40.8% compared to 68.5% (p < 0.001). CONCLUSION: Low HALP score was associated with unfavorable clinicopathological characteristics of ENKTL patients with low-risk and early-stage disease, suggesting that it may serve as an independent, negative prognostic indicator.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
- Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, China.
- Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, China. zouliqun1971@163.com.
Zitieren
APA
Li, N., Huang, J., Xie, Y., Feng, Y., Min, S., & Zou, L. Q. (2025). The prognostic value of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in low-risk and early-stage extranodal natural killer/T cell lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-025-06272-7
Vancouver
Li N, Huang J, Xie Y, Feng Y, Min S, Zou LQ. The prognostic value of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in low-risk and early-stage extranodal natural killer/T cell lymphoma. Annals of Hematology. 2025. doi:10.1007/s00277-025-06272-7
BibTeX
@article{Li2025,
author = {Li, Na and Huang, Jing and Xie, Yuping and Feng, You and Min, Shihui and Zou, Li-Qun},
title = {The prognostic value of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in low-risk and early-stage extranodal natural killer/T cell lymphoma},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06272-7}
}
EUVIMED